Akebia Therapeutics, Inc. (NASDAQ:AKBA) Director Duane Nash sold 1,188 shares of the stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $19.64, for a total value of $23,332.32. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA) remained flat at $19.23 during trading on Thursday. The company’s stock had a trading volume of 315,281 shares. The stock’s 50-day moving average price is $17.09 and its 200 day moving average price is $13.79. Akebia Therapeutics, Inc. has a 1-year low of $7.16 and a 1-year high of $20.25. The firm’s market capitalization is $351.91 million.

Akebia Therapeutics (NASDAQ:AKBA) last posted its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.53) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.36. The business had revenue of $28.52 million for the quarter, compared to analyst estimates of $26.50 million. On average, equities research analysts predict that Akebia Therapeutics, Inc. will post ($2.57) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This piece was first reported by Marea Informative and is the sole property of of Marea Informative. If you are accessing this piece on another domain, it was stolen and reposted in violation of United States and international copyright and trademark law. The original version of this piece can be viewed at http://www.mareainformativa.com/akebia-therapeutics-inc-akba-director-duane-nash-sells-1188-shares-of-stock/117800/.

Several research firms have recently weighed in on AKBA. HC Wainwright reissued a “buy” rating and set a $24.00 price target on shares of Akebia Therapeutics in a report on Wednesday, August 9th. BidaskClub cut Akebia Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, July 19th. ValuEngine raised Akebia Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Aegis reissued a “buy” rating on shares of Akebia Therapeutics in a report on Friday, June 30th. Finally, Royal Bank Of Canada began coverage on Akebia Therapeutics in a report on Thursday, September 14th. They set a “sector perform” rating and a $17.00 price target on the stock. Two research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $22.00.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Creative Planning lifted its position in Akebia Therapeutics by 2.9% during the second quarter. Creative Planning now owns 10,650 shares of the biopharmaceutical company’s stock valued at $153,000 after purchasing an additional 300 shares during the period. Rhumbline Advisers lifted its position in Akebia Therapeutics by 1.3% during the second quarter. Rhumbline Advisers now owns 41,510 shares of the biopharmaceutical company’s stock valued at $596,000 after purchasing an additional 518 shares during the period. Goldman Sachs Group Inc. lifted its position in Akebia Therapeutics by 1.2% during the first quarter. Goldman Sachs Group Inc. now owns 49,277 shares of the biopharmaceutical company’s stock valued at $453,000 after purchasing an additional 608 shares during the period. Legal & General Group Plc lifted its position in Akebia Therapeutics by 8.0% during the second quarter. Legal & General Group Plc now owns 9,672 shares of the biopharmaceutical company’s stock valued at $142,000 after purchasing an additional 714 shares during the period. Finally, Wells Fargo & Company MN lifted its position in Akebia Therapeutics by 1.0% during the second quarter. Wells Fargo & Company MN now owns 88,116 shares of the biopharmaceutical company’s stock valued at $1,266,000 after purchasing an additional 880 shares during the period. Institutional investors own 57.62% of the company’s stock.

About Akebia Therapeutics

Akebia Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company’s lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD).

Insider Buying and Selling by Quarter for Akebia Therapeutics (NASDAQ:AKBA)

Receive News & Stock Ratings for Akebia Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics Inc. and related stocks with our FREE daily email newsletter.